If this message does not display properly, please click here to launch your browser
| Building in BRIC—Negotiating the Challenges and Capitalizing on the Opportunities in Emerging Markets — A Webinar from Decision Resources | |||
Based on our report entitled Strategic Overview of Pricing and Reimbursement in the BRIC Markets, Decision Resources is offering an exclusive webinar entitled Building in BRIC—Negotiating the Challenges and Capitalizing on the Opportunities in Emerging Markets. Because this webinar will feature major report findings, it is ONLY available to purchasers of this report. Strategic Overview reports are a new offering within the Spectrum franchise. Please contact us to learn how you can purchase this report and attend the webinar. Faced with the prospect of a long-term decline in growth rates in mature markets, pharmaceutical companies are understandably drawn to emerging markets that hold out the promise of much faster growth. The “BRIC markets”—Brazil, Russia, India, and China—have been the focus of particular attention from the pharmaceutical industry. Multinational companies that want to rank among the leading players in the global pharmaceutical market of the future certainly cannot afford to ignore these expanding markets, but nor should they rush into these markets without an adequate understanding of the particular challenges they present. The emerging markets certainly offer rapid sales growth, but this expansion is generally from a relatively low base, particularly when the very large populations of some of these markets are taken into account. Pharmaceutical companies entering the emerging markets must also be prepared for deficient healthcare infrastructures and logistical difficulties in reaching consumers in remote rural markets. Multinational companies must also recognize that governments in emerging markets are not always very supportive of large foreign companies’ efforts to establish a commanding position in their pharmaceutical markets. Relatively weak intellectual property protection and the risk of counterfeiting are further hazards of some emerging markets. This webinar, presented by Decision Resources Analyst Neil Grubert, M.A., will examine the following topics across the four BRIC markets:
Mr. Grubert will conduct a live Q & A session after the presentation. Registration Building in BRIC—Negotiating the Challenges and Capitalizing on the Opportunities in Emerging Markets March 18, 2010 at 10 a.m. U.S. Eastern Time; 3 p.m. Central European Time (Paris). To learn how you can purchase this report and attend the webinar, please contact us using the information below.
In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||
Neil Grubert, M.A., has worked in the London office of Decision Resources for the past 13 years. As the director of pricing and reimbursement research, with responsibility for Spectrum’s Pharmaceutical Pricing, Reimbursement, and Market Access portfolio, he has written more than 100 reports in this subject area. Mr. Grubert was previously a project manager for Decision Resources, authoring Pharmacor and DecisionBase reports on a wide range of CNS and immune/inflammatory disorders. Before joining Decision Resources, he spent several years at Nicholas Hall & Company, a leading authority on the worldwide market for nonprescription medicines. Mr. Grubert is a graduate of the University of London. 